Deerfield Management Company, L.P. (Series C) Aligos Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.04 Billion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 17, 2021	SELL	$19.1 - $34.94 $11.5 Million - $21 Million	-600,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $7.92 Million - $19.6 Million	600,000 New	600,000 $16.6 Million

Others Institutions Holding ALGS

# of Institutions

Shares Held

227K

Call Options Held

Put Options Held

Black Rock Inc. New York, NY

227K
Shares

$2.44 Million
0.0% of portfolio
Nelson, Van Denburg & Campbell Wealth Management Group, LLC Omaha, NE

80
Shares

$860
0.0% of portfolio

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $427M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account